Mayes Patrick A 4

What Happened

• Patrick A. Mayes, Executive Vice President & Chief Scientific Officer of Incyte Corporation (INCY), was awarded 4,218 derivative securities on January 16, 2026. The reported acquisition price was $0.00, so no cash was paid at grant. This is an award/grant of derivative securities (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-01-16; filing/accession date: 2026-01-21 (filed timely).
• Transaction type/code: A — Grant, award or other acquisition (derivative securities).
• Quantity and price: 4,218 derivative units at $0.00 (total reported cash value $0.00 at grant).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: Options become exercisable in 37 installments beginning Jan 16, 2026; first 25% vests on July 15, 2026, with the remainder vesting monthly over three years.

Context

• This filing reports an award of derivative securities (an option-like award per the footnote). Such awards represent potential future ownership subject to vesting/exercise conditions and are not an immediate purchase or sale of common shares.
• The timely filing suggests compliance with SEC reporting deadlines; the grant itself does not necessarily indicate immediate buying or selling intent.